Reproducibility of exhaled nitric oxide measurements in overweight and obese adults by Willemien Thijs et al.
Thijs et al. BMC Research Notes 2014, 7:775
http://www.biomedcentral.com/1756-0500/7/775SHORT REPORT Open AccessReproducibility of exhaled nitric oxide
measurements in overweight and obese adults
Willemien Thijs1*, Renée de Mutsert2, Saskia le Cessie2,3, Pieter S Hiemstra1, Frits R Rosendaal2,
Saskia Middeldorp4 and Klaus F Rabe5Abstract
Background: Exhaled nitric oxide is a noninvasive measure of airway inflammation that can be detected by a
handheld device. Obesity may influence the reproducibility of exhaled nitric oxide measurements, by - for
instance – decreased expiratory reserve volume.
Findings: We analyzed triple exhaled nitric oxide measurements from 553 participants (aged 45 to 65 years with
a body mass index ≥27 kg/m2) of the Netherlands Epidemiology of Obesity Study. The interclass correlation
coefficient (single measurement reliability) was 0.965 (95% CI: 0.960, 0.970).
Conclusions: We conclude that for assessment of exhaled nitric oxide in large cohorts of overweight and obese
adults a single measurement suffices.
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Introduction
Exhaled nitric oxide (eNO) is a noninvasive marker of
inflammation in the airways. The levels of eNO correlate
well with other markers of inflammation in the airways
of asthmatics, such as sputum eosinophils and airway
eosinophilia in bronchial biopsies [1,2]. Measuring eNO
with a handheld device is a convenient way to assess air-
ways inflammation and has been used to study e.g. occu-
pational hazards or asthma [3,4]. The prevalence of
obesity has risen dramatically in the past decades and an
increasing proportion of participants in studies will be
overweight or obese [5]. Because eNO measurements
take time and generate costs it is important to establish
the reproducibility of eNO measurements in overweight
and obese adults.
How could obesity influence eNO measurements?
Obesity is associated with a loss in expiratory reserve
volume [6], which may influence eNO measurement that
require a slow and steady exhalation. In addition, obesity
is associated with low grade systemic inflammation [7]
which may be accompanied by airways inflammation* Correspondence: W.Thijs@lumc.nl
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unless otherwise stated.resulting in increased eNO levels. However, studies into
the association between obesity and levels of eNO show
conflicting results [8-11]. Therefore it is not clear
whether putatively increased eNO levels may contribute
to decreased reproducibility in obese subjects.
The ATS/ERS recommendations for eNO measure-
ments suggest two measurements of eNO [12]. Because
of the time requirement and costs associated with mul-
tiple eNO measurements in large scale studies, a single
measurement would be preferable. Reproducibility of
eNO measured by the handheld NIOX MINO has been
evaluated in children [13], adults [14], asthma patients
and pregnant women [15], but not in overweight and
obese individuals. Therefore, we used a triplicate meas-
urement to assess the reproducibility of eNO measured
by a handheld NIOX MINO in a cohort study of over-
weight and obese adults, with the aim to assess whether
a single measurement may suffice in large scale studies.
Materials and methods
The Netherlands Epidemiology of Obesity (NEO) Study
is a population-based cohort study in adults aged 45 to
65 years, with an oversampling of participants with over-
weight or obesity [16]. The study was approved by the
ethical committee of the Leiden University Medical Cen-
ter and all participants gave written informed consent.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics and eNO measurements of
the study population (n = 553)
Characteristic Median or % IQR
Age (years) 56 (50-61)
Sex (women %) 47 NA
Self reported asthma (%) 7 NA
BMI (kg/m2) 30 (28-33)
FEV1 % predicted 103 (92-114)
FVC % predicted 105 (96-115)
First nitric oxide (ppb) 17 (12-23)
Second nitric oxide (ppb) 17 (12-24)
Third nitric oxide (ppb) 17 (13-24)
BMI: Body mass index; IQR: Interquartile range; NA: not applicable; FEV1 %:
percent predicted of forced expiratory volume; FVC % percent predicted of
forced vital capacity; ppb: parts per billion.
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with a body mass index (BMI) ≥ 27 kg/m2. Completed
multiple questionnaires including self-reported asthma,
and anthropometric and maximal flow-volume curves
measurements were obtained. Exhaled nitric oxide was
measured using a portable analyzer, the NIOX MINO
(Aerocrine AB, Solna, Sweden). Participants performed a
10 seconds slow steady exhalation. Three successive re-
cordings at 1-minute intervals, expressed as parts per
billion (ppb), were made. The interclass correlation coef-



































Figure 1 Bland-Altman plot for the first two eNO measurements by th
the first and the second measurement.in all participants, participants with self reported asthma
and separately for participants with a BMI ≥ 35 and for
elevated mean eNO levels (>25 ppb and for >50) [17].
The mean intra-participant difference in eNO was calcu-
lated and a Bland-Altman plot was constructed. Statis-
tical analyses were performed with SPSS 20.0 software
(SPSS Inc., Chicago, IL).
Results
Of the first 630 participants of the NEO study, 46 partic-
ipants did not perform eNO measurements because they
did not visit the lung function department due to logistic
problems. In another 31 patients, no measurements were
obtained because of inability to perform the technique
or because of a technical failure with the nitric oxide
machines. As a result, the present analysis includes 553
participants who performed all three eNO measure-
ments. The characteristics of the study population and
results of eNO measurements are presented in Table 1.
The ICC (single measurement reliability) for all partici-
pants was 0.965 (95% CI: 0.960, 0.970), whereas it was
0.926 (95% CI: 0.926, 0.965) for the participants with a
BMI ≥ 35 (n = 92). The ICC (single measurement reliabil-
ity) for all participants with asthma (n = 39) was 0.988
(95% CI: 0.979, 0.993), whereas it was 0.932 (95% CI:
0.818, 0.981) for the participants with asthma and a
BMI ≥ 35 (n = 10). The ICC for all eNO measurements
that exceeded 25 ppb (n = 109) was 0.949 (95% CI: 0.931,nd NO measurements (ppb)
e NIOX MINO (n = 553). The dots represent the difference between
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0.911 (95% CI: 0.818, 0.963). The mean intra-participant
difference in eNO for all participants was for the second
and first reading: -0.05 ppb (95% CI: -7.14, 7.04); third
and first reading -0.15 ppb (95% CI: -6.8, 7.6); and third
and second reading -0.13 ppb (95% CI: -5.9, 6.5). A
Bland-Altman plot was constructed for the first two
measurements (Figure 1).
Discussion
The ICC and mean intra-participant difference in eNO
for all 553 participants was in line with previous repro-
ducibility studies performed on the NIOX MINO in
other populations [13,14]. The ICC for participants with
a BMI ≥ 35 kg/m2 was slightly lower (but clinically not
relevant) than within the whole group, possibly as a re-
sult of decreased expiratory reserve volumes. Low grade
inflammation associated with obesity appears a less likely
explanation for the small loss in reproducibility because
only early studies report a positive correlation between
BMI and eNO [8,9]; later studies have not been able to
reproduce these initial findings [10,11]. The reproduci-
bility in participants with self reported asthma was in
line with the results in the whole group but within our
study the reproducibility at higher eNO levels was
slightly lower. In earlier study by Selby et al. [13] it is
concluded that for individual absolute levels two mea-
surements are needed. Similarly, we conclude that in
clinical practice two eNO measurements are advised but
despite small differences of ICC in different analyses,
our results demonstrate that in large cohorts of over-
weight and obese adults a single eNO measurement suf-
fices, which will have significant logistical and financial
consequences for cohort studies.
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